A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients

Saira Sanjida, Monika Janda, David Kissane, Joanne Shaw, Sallie Anne Pearson, Tracey DiSipio, Jeremy Couper

Research output: Contribution to journalReview ArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Background: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancer patients, and differences by study or patient characteristics. Methods: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords ‘psychotropic’, ‘antidepressants’, ‘prescription’ and ‘cancer’. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. Results: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancer patients was 15.6% (95% CI = 13.3–18.3). Prescription was significantly less common in studies from Asia (7.4%; 95% CI = 4.3–12.5), more common in female (22.6%; 95% CI = 16.0–31.0) or breast cancer patients (22.6%; 95% CI = 16.0–30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancer patients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. Conclusions: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug–drug interactions are identified and managed.

Original languageEnglish
Pages (from-to)1002-1016
Number of pages15
JournalPsycho-Oncology
Volume25
Issue number9
DOIs
Publication statusPublished - 1 Sep 2016

Cite this

Sanjida, Saira ; Janda, Monika ; Kissane, David ; Shaw, Joanne ; Pearson, Sallie Anne ; DiSipio, Tracey ; Couper, Jeremy. / A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. In: Psycho-Oncology. 2016 ; Vol. 25, No. 9. pp. 1002-1016.
@article{4b8cbde0eacd475ca878243697e6a8d3,
title = "A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients",
abstract = "Background: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancer patients, and differences by study or patient characteristics. Methods: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords ‘psychotropic’, ‘antidepressants’, ‘prescription’ and ‘cancer’. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. Results: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancer patients was 15.6{\%} (95{\%} CI = 13.3–18.3). Prescription was significantly less common in studies from Asia (7.4{\%}; 95{\%} CI = 4.3–12.5), more common in female (22.6{\%}; 95{\%} CI = 16.0–31.0) or breast cancer patients (22.6{\%}; 95{\%} CI = 16.0–30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancer patients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. Conclusions: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug–drug interactions are identified and managed.",
author = "Saira Sanjida and Monika Janda and David Kissane and Joanne Shaw and Pearson, {Sallie Anne} and Tracey DiSipio and Jeremy Couper",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/pon.4048",
language = "English",
volume = "25",
pages = "1002--1016",
journal = "Psycho-Oncology",
issn = "1057-9249",
publisher = "John Wiley & Sons",
number = "9",

}

Sanjida, S, Janda, M, Kissane, D, Shaw, J, Pearson, SA, DiSipio, T & Couper, J 2016, 'A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients', Psycho-Oncology, vol. 25, no. 9, pp. 1002-1016. https://doi.org/10.1002/pon.4048

A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. / Sanjida, Saira; Janda, Monika; Kissane, David; Shaw, Joanne; Pearson, Sallie Anne; DiSipio, Tracey; Couper, Jeremy.

In: Psycho-Oncology, Vol. 25, No. 9, 01.09.2016, p. 1002-1016.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients

AU - Sanjida, Saira

AU - Janda, Monika

AU - Kissane, David

AU - Shaw, Joanne

AU - Pearson, Sallie Anne

AU - DiSipio, Tracey

AU - Couper, Jeremy

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancer patients, and differences by study or patient characteristics. Methods: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords ‘psychotropic’, ‘antidepressants’, ‘prescription’ and ‘cancer’. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. Results: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancer patients was 15.6% (95% CI = 13.3–18.3). Prescription was significantly less common in studies from Asia (7.4%; 95% CI = 4.3–12.5), more common in female (22.6%; 95% CI = 16.0–31.0) or breast cancer patients (22.6%; 95% CI = 16.0–30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancer patients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. Conclusions: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug–drug interactions are identified and managed.

AB - Background: Antidepressants are commonly used for the pharmacological treatment of depression. We aimed to summarise the prevalence of antidepressant prescription to cancer patients, and differences by study or patient characteristics. Methods: PubMed, Embase, Web of Science, Scopus and psychINFO were searched using keywords ‘psychotropic’, ‘antidepressants’, ‘prescription’ and ‘cancer’. Prevalence of antidepressants, type, dose and follow-up of antidepressants and prescriber details were extracted. Results: Overall, 1537 articles between 1979 and February 2015 were found, 38 met the inclusion criteria and were reviewed according to PRISMA guidelines. The prevalence rate of prescribing antidepressants to cancer patients was 15.6% (95% CI = 13.3–18.3). Prescription was significantly less common in studies from Asia (7.4%; 95% CI = 4.3–12.5), more common in female (22.6%; 95% CI = 16.0–31.0) or breast cancer patients (22.6%; 95% CI = 16.0–30.9). Selective serotonin reuptake inhibitors were the most frequently prescribed antidepressants. General practitioners and psychiatrists, followed by oncologists, were identified as the major providers of antidepressant prescriptions to cancer patients. Few studies reported the exact dose, length of time drugs were prescribed for or follow-up regimens. Conclusions: There is considerable variation in the prescribing patterns of antidepressants across the world, with few studies reporting robust data on exact dose or follow-up regimens. Prospective studies that monitor antidepressant prescribing, including details of reasons for prescribing and the healthcare providers involved, dose, change in dose or type of medication and follow-up are needed to ascertain whether patients are being treated optimally and if side effects or drug–drug interactions are identified and managed.

UR - http://www.scopus.com/inward/record.url?scp=84985962926&partnerID=8YFLogxK

U2 - 10.1002/pon.4048

DO - 10.1002/pon.4048

M3 - Review Article

VL - 25

SP - 1002

EP - 1016

JO - Psycho-Oncology

JF - Psycho-Oncology

SN - 1057-9249

IS - 9

ER -